A5007377058- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Potassium and Related Disorders
- Chronic Disease Management Strategies
- Mechanical Circulatory Support Devices
- Electrolyte and hormonal disorders
- Atrial Fibrillation Management and Outcomes
- Dialysis and Renal Disease Management
- Diabetes Treatment and Management
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac Health and Mental Health
- Cardiac Structural Anomalies and Repair
- Cardiovascular and exercise physiology
- Cardiac Valve Diseases and Treatments
- Pharmaceutical Practices and Patient Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Erythropoietin and Anemia Treatment
- Cancer Diagnosis and Treatment
- Cardiac Imaging and Diagnostics
- Hormonal Regulation and Hypertension
- Pelvic floor disorders treatments
- Renal function and acid-base balance
- Ion Transport and Channel Regulation
- Frailty in Older Adults
Hospital Universitario de Getafe
2016-2025
Universidad Europea
2024-2025
Centro de Implantología Cirugía Oral y Maxilofacial
2024
Hospital Universitario de La Princesa
2006-2023
Sociedad Española de Medicina Interna
2019-2023
Hospital Comarcal de Inca
2023
Hospital Universitario del Henares
2011-2015
To evaluate whether the addition of hydrochlorothiazide (HCTZ) to intravenous furosemide is a safe and effective strategy for improving diuretic response in acute heart failure (AHF).A prospective, double-blind, placebo-controlled trial, including patients with AHF randomized receive HCTZ or placebo an regimen. The coprimary endpoints were changes body weight patient-reported dyspnoea 72 h after randomization. Secondary outcomes included metrics mortality/rehospitalizations at 30 90 days....
The coexistence of heart and kidney diseases, also called cardiorenal syndrome, is increasingly common, leads to a significant impact on morbidity mortality, poses diagnostic therapeutic difficulties. There risk-treatment paradox, such that patients with the highest risk are treated lesser disease-modifying medical therapies. In this document, different scientific societies propose practical approach systematically address optimize therapies related comorbidities in chronic disease beyond...
Aims: To determine the projected benefits of dapagliflozin after an acute heart failure (HF) event in Spain. Methods: A multicenter and prospective study that included subjects aged 50 years or older consecutively admitted with HF to internal medicine departments The clinical were calculated via pooled analysis DAPA-HF DELIVER trials. Results: total 5644 analyzed, whom 79.2% eligible for dapagliflozin, according criteria Full implementation would imply a 1-year absolute risk reduction 2.3%...
Aims Renal function is an important prognostic factor in heart failure. The aim of this study was to compare the predictive value estimated renal calculated by Chronic Kidney Disease-Epidemiology Collaboration equation (CKD-EPI) and abbreviated Modification Diet Disease (MDRD-4) for long-term all-cause mortality patients admitted acute decompensated failure (ADHF) with both preserved ejection fraction (HF-PEF) reduced (HF-REF). Methods Results We evaluated included Spanish National Registry...
Aims: To address the projected clinical benefits of dapagliflozin among patients with heart failure (HF) mildly reduced ejection fraction (HFmrEF) and preserved (HFpEF). Methods: A multicenter, prospective, cohort study ≥50 years admitted HF to Spanish internal medicine departments. The were calculated from DELIVER trial. Results: total 4049 included; 3271 (80.8%) eligible for treatment, according criteria. Within 1 year after discharge, 22.2% rehospitalized 21.6% died. Implementation would...